ISSN: 2574-7797
Authors: Amith B*, Basavaraj BV and Nikitha S
Solid lipid nanoparticles were prepared by using the solvent evaporation method. The prepared solid lipid nanoparticles of felodipine from different batches were weighed accurately and filled into appropriate-sized capsules for further evaluation. The prepared nanoformulation was tested in vitro for drug entrapment efficiency found to be 97-99% for the formulation with soya lecithin and glyceryl mono-stearate and percentage yield. The results of the in vitro drug release study for all formulations performed at gastric pH 1.2 indicated that the drug was released in an immediate manner within 60 minutes, which could be due to a burst effect or a faster rate of drug release due to smaller particle size SLN13 the concentration of Glycerol Monosterate- 576.522mg and Poloxamer 188. In vitro release data from standardised nanoformulations was fitted to various release kinetics models for the drug release mechanism. The optimised formulation demonstrated improved drug release and entrapment efficiency, and in vitro release data were fitted to various kinetic models to better understand the drug release mechanism. In vitro assay results were ranged between 76.5 to 96%, Zeta potential -40.75 ± 2.33 (mV) ± SD, entrapment efficiency 99.32. Accelerated stability studies for standardised nanoformulations were performed for 6 months in accordance with standard ICH guidelines, and no appreciable changes in the physical appearance, drug content, and in vitro drug release rates of the nanoformulations were observed. As a result of the study's evidence, it is concluded that felodipineloaded solid lipid nanoparticles are the best choice for hypertension.
Keywords: Hypertension; Felodipine; Solid Lipid Nanoparticles; In vitro Studies; Emulsifiers; Korsmeyer-Pappas Equation
